Please ensure Javascript is enabled for purposes of website accessibility

Kids May Be the Hidden Carriers of COVID-19

By Brian Orelli, PhD - Updated Mar 5, 2020 at 4:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Asymptomatic patients are a major vector spreading the coronavirus, and young people appear to be getting mostly very mild cases.

SARS-CoV-2, the coronavirus that causes COVID-19, affects those it infects in widely varied ways. Its symptoms of fever, coughing, and fatigue can be so mild that a person can go about their daily routine normally, or so severe that they develop into pneumonia, which is the path that is leading to the disease's fatalities. But it is the former group -- and those who are infected but show no symptoms at all -- that have allowed the disease to spread so widely. There have now been over 92,000 confirmed cases worldwide according to data tracked by Johns Hopkins University's Center for Systems Science and Engineering.

A former director of the U.S. Centers for Disease Control and prevention hypothesizes that children, who are rarely being diagnosed with the illness -- perhaps because they don't exhibit as intense symptoms as adults -- may be the secret carriers of the disease, according to an article in The New York Post.

Doctor listening to a child's heart with a stethoscope

Image source: Getty Images.

As Dr. Tom Frieden noted, doctors reported in the medical journal The Lancet on a family of six patients, five of whom had traveled to Wuhan, China. One of the family members was a 10-year-old who was asymptomatic, but who nonetheless tested positive for the coronavirus and had signs of an infection on a chest X-ray.

There aren't any approved treatments yet for COVID-9, but Gilead Sciences (GILD -0.51%) is currently testing its Ebola virus drug remdesivir in a late-stage clinical trial. Moderna (MRNA 1.80%) has developed mRNA-1273, a vaccine for the coronavirus, and plans to start a clinical trial next month. Inovio Pharmaceuticals (INO 0.28%) also has a vaccine candidate, INO-4800, and intends to start a clinical trial in 30 healthy volunteers in the U.S. next month. Larger drugmakers, such as Johnson & Johnson (JNJ 0.11%) and Sanofi (SNY -4.52%), have also announced that they're working on vaccines and treatments for the disease.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.18 (0.11%) $0.19
Sanofi Stock Quote
Sanofi
SNY
$50.29 (-4.52%) $-2.38
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.16 (-0.51%) $0.32
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.79 (0.28%) $0.01
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$145.38 (1.80%) $2.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.